Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs

Joost W. Geenen (Lead / Corresponding author), Ekaterina V. Baranova, Folkert W. Asselbergs, Anthonius de Boer, Rick A. Vreman, Colin N. A. Palmer, Anke Hilse Maitland-van der Zee, Anke M. Hövels, PREDICTION-ADR Consortium

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Aim: To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.

Materials & Methods: A decision tree was used.

Results: With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.

Conclusion: This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.

Original languageEnglish
Issue number12
Early online date26 Jul 2017
Publication statusPublished - Aug 2017


  • Journal article
  • Adverse drug reactions
  • Angioedema
  • ACE inhibitors ACE inhibitor induced angioedema
  • Cardiovascular drugs
  • Cost–effectiveness
  • Health technology assessment
  • Pharmacogenomic test


Dive into the research topics of 'Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs'. Together they form a unique fingerprint.

Cite this